Evidence map›Paper›PMID 38409165›Full record

ArticleNPJ vaccines2024

Conserved molecular chaperone PrsA stimulates protective immunity against group A Streptococcus.

Chien-Yu Lai, Jia-Xun Xie, Meng-Chih Lai, Zhao-Yi Wu, Jr-Shiuan Lin, Yu-Tsung Huang, Chia-Yu Chi, Chuan Chiang-Ni, Mark J Walker, Yung-Chi Chang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Identification of immunostimulatory antigens in Group AProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Chien-Yu LaiGraduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan.
Jia-Xun XieGraduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan.
Meng-Chih LaiGraduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan.
Zhao-Yi WuGraduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan.
Jr-Shiuan LinGraduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan.ORCID http://orcid.org/0000-0003-0583-148X
Yu-Tsung HuangDepartment of Laboratory Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan.
Chia-Yu ChiNational Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Miaoli, 300, Taiwan.
Chuan Chiang-NiDepartment of Microbiology and Immunology, College of Medicine, Chang Gung University, Taoyuan, 333, Taiwan.
Mark J WalkerCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.
Yung-Chi ChangGraduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan. yungchiychang@ntu.edu.tw.ORCID http://orcid.org/0000-0001-5153-0907
National Taiwan University · TWChang Gung University · TWNational Health Research Institutes · TWNational Taiwan University Hospital · TWThe University of Queensland · AU

Funding

Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate ModelsR01AI173689 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Victor Nizet, Mark Joseph Walker · 2023 to 2026
$2.8M
Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan) MOST 111-2628-B-002-033-MY3National Taiwan University (NTU) NTU-CC-112L892702National Taiwan University (NTU) NTU-CDP-111L7769National Taiwan University (NTU) NTU-CDP-112L7740NIAID NIH HHS R01 AI173689
6 · The paper itself

Abstract

Group A Streptococcus (GAS) is a significant human pathogen that poses a global health concern. However, the development of a GAS vaccine has been challenging due to the multitude of diverse M-types and the risk of triggering cross-reactive immune responses. Our previous research has identified a critical role of PrsA1 and PrsA2, surface post-translational molecular chaperone proteins, in maintaining GAS proteome homeostasis and virulence traits. In this study, we aimed to further explore the potential of PrsA1 and PrsA2 as vaccine candidates for preventing GAS infection. We found that PrsA1 and PrsA2 are highly conserved among GAS isolates, demonstrating minimal amino acid variation. Antibodies specifically targeting PrsA1/A2 showed no cross-reactivity with human heart proteins and effectively enhanced neutrophil opsonophagocytic killing of various GAS serotypes. Additionally, passive transfer of PrsA1/A2-specific antibodies conferred protective immunity in infected mice. Compared to alum, immunization with CFA-adjuvanted PrsA1/A2 induced higher levels of Th1-associated IgG isotypes and complement activation and provided approximately 70% protection against invasive GAS challenge. These findings highlight the potential of PrsA1 and PrsA2 as universal vaccine candidates for the development of an effective GAS vaccine.

Identifiers

PMID38409165
PMCPMC10897429
OpenAlexW4392167134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.